
Siglec-H, Mouse, mAb 440c, biotinylated
The monoclonal antibody 440c reacts with Siglec-H, a cell-surface receptor molecule selectively expressed on murine natural interferon producing cells (IPC), also called mouse plasmacytoid dendritic cells (pDC). Siglec H is unique among Sialic acid-binding Ig-like lectins (Siglecs) proteins because it associates with the adaptor protein DAP12. DAP12 recognize certain viruses and CpG-DNA through TLR9, resulting in secretion of IFN-alpha, IL-12 and proinflammatory chemokines. Together these cytokines and chemokines recruite and activate NK cells and T cells as well as modulating the antigen presenting function of dendritic cells (DC). IPC themselves also function as antigen presenting cells that expand memory T cells and induce Th1 differentiation. Therefore IPC may provide a first line of host defense against viral infections by activating both innate and adaptive responses in vivo. The monoclonal antibody 440c exclusively recognizes mouse Siglec-H in all lymphoid organs under both normal and inflammatory conditions. Siglec-H is normal present in the T cell zone of lymph nodes and spleen. Incubation of IPC with antibody 440c in vitro or administration of antibody 440c in vivo reduces secretion of IFN-alpha in response to CpG DNA without causing IPC depletion.
Calculate your ELISA data easily
With the ELISA calculator you can easily calculate ELISA data. Assayfit Pro helps to perform curve fitting. The calculator generates advanced reports, fit graph, fit parameters and goodness of fit are shown.
Latest Hycult Biotech news
- Discover Cross-Reactive Complement ELISA for NHP ResearchBridging Human and NHP Complement Research. At Hycult Biotech, we understand the importance of testing therapeutic agents on non-human primates (NHP) samples in order to get approval to enter clinical phases. That is why we have committed to the following initiative: Testing our existing complement ELISA assays for NHP research. Why Non Human Primate Samples… Read more: Discover Cross-Reactive Complement ELISA for NHP Research
- New Human Complement Pathway AssaysWe are very proud of our newly developed human classical and alternative complement pathway assays. They are produced in response to a growing demand for quantitative investigation of complement inhibitors or regulators at lower sample dilutions. This development aims to address the issue of false negative results, enabling more accurate and reliable analysis of complement… Read more: New Human Complement Pathway Assays
- Navigating the pitfalls in complement analysisOur colleague Erik Toonen shared his experience on how to analyze complement at the Complement-based Drug Development Summit in Boston in September 11-13th, 2023. He showed valuable insights on analyzing complements. For accurate complement analysis, it is important that not only the correct technique is used but also that pre-analytical sample handling is performed in… Read more: Navigating the pitfalls in complement analysis